These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15665626)

  • 21. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
    Powell S; Dudek AZ
    Anticancer Res; 2009 Oct; 29(10):4189-93. PubMed ID: 19846971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of outpatient intravenous interleukin-2 and famotidine in metastatic clear cell kidney cancer.
    Quan WD; Quan FM
    Cancer Biother Radiopharm; 2014 Mar; 29(2):58-61. PubMed ID: 24251758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
    Lotze MT; Frana LW; Sharrow SO; Robb RJ; Rosenberg SA
    J Immunol; 1985 Jan; 134(1):157-66. PubMed ID: 3871099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
    Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
    Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2.
    Eastman ME; Khorsand M; Maki DG; Williams EC; Kim K; Sondel PM; Schiller JH; Albertini MR
    Cancer; 2001 Feb; 91(4):806-14. PubMed ID: 11241250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
    Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
    Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.
    Davis ID; Skrumsager BK; Cebon J; Nicholaou T; Barlow JW; Moller NP; Skak K; Lundsgaard D; Frederiksen KS; Thygesen P; McArthur GA
    Clin Cancer Res; 2007 Jun; 13(12):3630-6. PubMed ID: 17575227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
    Bar MH; Sznol M; Atkins MB; Ciobanu N; Micetich KC; Boldt DH; Margolin KA; Aronson FR; Rayner AA; Hawkins MJ
    J Clin Oncol; 1990 Jul; 8(7):1138-47. PubMed ID: 2358835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
    Reuben JM; Lee BN; Li C; Gomez-Navarro J; Bozon VA; Parker CA; Hernandez IM; Gutierrez C; Lopez-Berestein G; Camacho LH
    Cancer; 2006 Jun; 106(11):2437-44. PubMed ID: 16615096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Syndrome of inappropriate antidiuretic hormone secretion caused by high-dose bolus interleukin-2 therapy for metastatic melanoma.
    Green MR; Woolery JE; Elquza E
    Am J Ther; 2011 Sep; 18(5):e159-61. PubMed ID: 20592664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.
    Lin CC; Hsu CH; Huang CY; Cheng AL; Chen J; Vogelzang NJ; Pu YS
    Cancer; 2006 Mar; 106(6):1269-75. PubMed ID: 16470604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
    Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
    J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between development of pulmonary edema and response of pulmonary metastases of metastatic melanoma and kidney cancer to high-dose continuous-infusion interleukin-2.
    Quan WD; Khan N; Ramirez M; Taylor WC; Quan F; Vinogradov M; Walker P
    Cancer Biother Radiopharm; 2005 Apr; 20(2):151-4. PubMed ID: 15869448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
    Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
    Asemissen AM; Scheibenbogen C; Letsch A; Hellstrand K; Thorén F; Gehlsen K; Schmittel A; Thiel E; Keilholz U
    Clin Cancer Res; 2005 Jan; 11(1):290-7. PubMed ID: 15671558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Amato RJ; Malya R; Rawat A
    Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
    van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
    Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.
    Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Levitt D; Fefer A
    J Clin Oncol; 1988 Apr; 6(4):669-78. PubMed ID: 3258631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bolus followed by continuous infusion interleukin-2 in patients with metastatic malignant melanoma and kidney cancer previously treated with interleukin-2.
    Quan WD; Quan FM
    Cancer Biother Radiopharm; 2003 Aug; 18(4):535-8. PubMed ID: 14503947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.